0001328143-21-000007.txt : 20210201 0001328143-21-000007.hdr.sgml : 20210201 20210201080522 ACCESSION NUMBER: 0001328143-21-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210130 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20210201 DATE AS OF CHANGE: 20210201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 21574408 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 8-K 1 adms-20210130.htm 8-K adms-20210130
0001328143FALSE00013281432021-01-302021-01-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 30, 2021
ADAMAS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
 
001-36399
 
42-1560076
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer Identification No.)
1900 Powell Street, Suite 1000
Emeryville, CA 94608
(Address of principal executive office)
Registrant’s telephone number, including area code (510) 450-3500
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per shareADMSThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 1.01    Entry Into a Material Definitive Agreement.
 
As previously disclosed, Adamas Pharma, LLC, a wholly-owned subsidiary of Adamas Pharmaceuticals, Inc. (the “Company”) is involved in a lawsuit against Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA), Inc. (collectively “Zydus”) in the United States District Court for the District of New Jersey alleging infringement of the Company’s patents by Zydus. On January 30, 2021, the Company entered into a definitive agreement (the “Definitive Agreement”) with Zydus pursuant to which the parties agreed to end the lawsuit and dismiss it without prejudice. Pursuant to the Definitive Agreement, the Company grants a license to make, use, sell, offer to sell and import a generic version of GOCOVRI® (amantadine) extended release capsules, effective as of March 4, 2030, or earlier in certain circumstances typical for such agreements. In addition, the Definitive Agreement contains provisions that may accelerate the license date, including if unit sales of GOCOVRI in the 12-month period ending July 31, 2025 or any subsequent 12-month period decline by a specified percentage below GOCOVRI unit sales in the year ended December 31, 2019.

The Definitive Agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice. The Company expects to file the Definitive Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2021.
2

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Adamas Pharmaceuticals, Inc.
Dated: February 1, 2021By:/s/ Christopher B. Prentiss
  Christopher B. Prentiss
  Chief Financial Officer

3
 EX-101.SCH 2 adms-20210130.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 adms-20210130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 adms-20210130_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 adms-20210130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two Document Information [Line Items] Document Information [Line Items] City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 6 adms-20210130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 adms-20210130_htm.xml IDEA: XBRL DOCUMENT 0001328143 2021-01-30 2021-01-30 0001328143 false 8-K 2021-01-30 ADAMAS PHARMACEUTICALS, INC. DE 001-36399 42-1560076 1900 Powell Street Suite 1000 Emeryville CA 94608 510 450-3500 false false false false Common Stock, par value $0.001 per share ADMS NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Jan. 30, 2021
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Jan. 30, 2021
Entity Incorporation, State or Country Code DE
Entity File Number 001-36399
Entity Tax Identification Number 42-1560076
Entity Address, Address Line One 1900 Powell Street
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 450-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ADMS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001328143
Amendment Flag false
Entity Registrant Name ADAMAS PHARMACEUTICALS, INC.
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://adamaspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports adms-20210130.htm adms-20210130.xsd adms-20210130_cal.xml adms-20210130_def.xml adms-20210130_lab.xml adms-20210130_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adms-20210130.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "adms-20210130_cal.xml" ] }, "definitionLink": { "local": [ "adms-20210130_def.xml" ] }, "inline": { "local": [ "adms-20210130.htm" ] }, "labelLink": { "local": [ "adms-20210130_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "adms-20210130_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "adms-20210130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adms", "nsuri": "http://adamaspharma.com/20210130", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adms-20210130.htm", "contextRef": "ib7035bcdde964497a7b289eb17f906a9_D20210130-20210130", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://adamaspharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adms-20210130.htm", "contextRef": "ib7035bcdde964497a7b289eb17f906a9_D20210130-20210130", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001328143-21-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001328143-21-000007-xbrl.zip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end